|
|
|
|
LEADER |
00000cam a2200000Ia 4500 |
001 |
EBSCO_ocn852757293 |
003 |
OCoLC |
005 |
20231017213018.0 |
006 |
m o d |
007 |
cr cnu---unuuu |
008 |
130713s2013 enk ob 001 0 eng d |
040 |
|
|
|a EBLCP
|b eng
|e pn
|c EBLCP
|d YDXCP
|d N$T
|d OCLCQ
|d DEBSZ
|d IDEBK
|d U3G
|d OCLCF
|d E7B
|d OCLCQ
|d AGLDB
|d MOR
|d PIFAG
|d ZCU
|d MERUC
|d OCLCQ
|d U3W
|d OCL
|d STF
|d WRM
|d OCLCQ
|d CUY
|d VTS
|d NRAMU
|d INT
|d OCLCQ
|d M8D
|d HS0
|d OCLCQ
|d OCLCO
|d UKAHL
|d OCLCQ
|
019 |
|
|
|a 847837411
|
020 |
|
|
|a 9781847359773
|q (electronic bk.)
|
020 |
|
|
|a 1847359779
|q (electronic bk.)
|
020 |
|
|
|a 1847359760
|
020 |
|
|
|a 9781847359766
|
029 |
1 |
|
|a AU@
|b 000053034719
|
029 |
1 |
|
|a AU@
|b 000055359091
|
029 |
1 |
|
|a DEBBG
|b BV043153871
|
029 |
1 |
|
|a DEBBG
|b BV044176380
|
029 |
1 |
|
|a DEBSZ
|b 42125081X
|
029 |
1 |
|
|a DEBSZ
|b 431443807
|
029 |
1 |
|
|a NZ1
|b 15588721
|
035 |
|
|
|a (OCoLC)852757293
|z (OCoLC)847837411
|
050 |
|
4 |
|a QK981.5 .Z384 2013
|
072 |
|
7 |
|a SCI
|x 011000
|2 bisacsh
|
082 |
0 |
4 |
|a 581.87328
|2 22
|
049 |
|
|
|a UAMI
|
100 |
1 |
|
|a Zhu, Jianwei.
|
245 |
1 |
0 |
|a Update on Production of Recombinant Therapeutic Protein :
|b Transient Gene Expression.
|
260 |
|
|
|a Shrewsbury :
|b ISmithers Rapra Publishing,
|c 2013.
|
300 |
|
|
|a 1 online resource (188 pages)
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
588 |
0 |
|
|a Print version record.
|
520 |
|
|
|a Over the past decade, the transient gene expression (TGE) technology platform has been actively pursued to produce a wide range of therapeutic proteins, monoclonal antibodies, and vaccines for mainly preclinical assessment, due to its short development times and low overall cost. This book updates the latest advances in the field, with focusing on systematic description of the technology from cell lines, cell culture conditions, vector construction, expression strategy, current protocols, optimisation of the procedure, and potential for clinical application. As a conclusion, the author foresee.
|
504 |
|
|
|a Includes bibliographical references at the end of each chapters and index.
|
505 |
0 |
|
|a Acknowledgements ; Preface ; Contributors ; 1 Transient Gene Expression in Different Expression Systems ; 1.1 Introduction ; 1.2 Transient Gene Expression versus Stable Gene Expression ; 1.3 Transient Gene Expression in Different Systems ; 1.3.1 Mammalian Cell Systems ; 1.3.2 Plant Systems ; 1.3.3 Insect Cell Systems ; 1.3.4 Stem Cell Systems ; References ; 2 Recent Advances in Transient Gene Expression Protocol ; 2.1 Vectors ; 2.1.1 Viral Vector ; 2.1.1.1 Adenovirus ; 2.1.1.2 Lentiviruses ; 2.1.1.3 Baculovirus ; 2.1.1.4 Vaccinia Virus
|
505 |
8 |
|
|a 2.1.1.5 Alphavirus 2.1.2 Nonviral Vectors ; 2.2 Construction for Expression ; 2.2.1 Promoter ; 2.2.2 Other Construction Components ; 2.2.3 Plasmid Preparation and Quality ; 2.3 Nonviral Gene Delivery ; 2.3.1 Electroporation Methods ; 2.3.2 Chemical Methods ; 2.3.2.1 Calcium Phosphate ; 2.3.2.2 Cationic Lipids ; 2.3.2.3 Polythylenimine ; 2.4 Cell Lines used in Transient Gene Expression ; 2.4.1 Human Embryonic Kidney 293 Cells ; 2.4.2 Chinese Hamster Ovary Cells ; 2.4.3 Other Cell Lines ; 2.4.3.1 Hybrid of Human Kidney and B Cells-11 ; 2.4.3.2 CAP-T Cell Line
|
505 |
8 |
|
|a 2.4.3.3 CAP-T versus Chinese Hamster Ovary versus Human Embryonic Kidney 293-6E and Hybrid of Huma 2.4.3.4 Huh-7 Cell Line ; 2.4.3.5 VERO Cell Line ; 2.4.3.6 PER.C6 Cell Line ; 2.5 Current Transient Gene Expression Protocols ; 2.5.1 Shake Flask Protocol for Volumes of Normal and High Density Cell Cultures Greater than One Lit; 2.5.2 Protocol for Large-scale Transient Transfection in the Wave Bioreactor [71, 110] ; 2.5.2.1 Large scale (20 L) Chinese Hamster Ovary Cell Transfection in Wave Bioreactor [110]
|
505 |
8 |
|
|a 2.5.2.2 Large scale (20 L) Human Embryonic Kidney 293 Cell Transfection in Wave Bioreactor [71] 2.5.3 High Density Large-scale Transfection of Mammalian Cells [109] ; 2.5.3.1 Cell Cultivation ; 2.5.3.2 Cell Expansion for Transfection ; 2.5.4 100 L Transient Gene Expression Protocol [4] ; 2.5.5 Purification of Products from Transient Gene Expression ; 2.5.5.1 Purification of a Monoclonal Antibody from Transient Gene Expression ; 2.5.5.2 Purification of a Recombinant Protein from Transient Gene Expression ; References
|
505 |
8 |
|
|a 3 Optimisation of Transient Gene Expression for Therapeutic Protein Production 3.1 Optimisation of the Transient Gene Expression Conditions ; 3.1.1 Medium Optimisation ; 3.1.1.1 Peptones ; 3.1.1.2 Valproic Acid ; 3.1.1.3 Other Additives ; 3.1.2 Optimisation of Transient Gene Expression Conditions and Procedures ; 3.1.2.1 Process Design ; 3.1.2.2 Optimisation of Culture Conditions ; 3.1.3 Construction Optimisation ; 3.1.3.1 Promoter ; 3.1.3.2 Codon Optimisation ; 3.1.3.3 Leader Sequence ; 3.1.3.4 Other Genetic Elements ; 3.1.3.4.1 Post-transcriptional Regulatory Elements
|
590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
650 |
|
0 |
|a Recombinant proteins
|x Therapeutic use.
|
650 |
|
0 |
|a Gene expression.
|
650 |
|
6 |
|a Protéines recombinantes
|x Emploi en thérapeutique.
|
650 |
|
6 |
|a Expression génique.
|
650 |
|
7 |
|a SCIENCE
|x Life Sciences
|x Botany.
|2 bisacsh
|
650 |
|
7 |
|a Gene expression.
|2 fast
|0 (OCoLC)fst00939613
|
856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=591459
|z Texto completo
|
938 |
|
|
|a Askews and Holts Library Services
|b ASKH
|n AH27120691
|
938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL1220690
|
938 |
|
|
|a ebrary
|b EBRY
|n ebr10717795
|
938 |
|
|
|a EBSCOhost
|b EBSC
|n 591459
|
938 |
|
|
|a ProQuest MyiLibrary Digital eBook Collection
|b IDEB
|n cis25644978
|
938 |
|
|
|a YBP Library Services
|b YANK
|n 10760993
|
938 |
|
|
|a YBP Library Services
|b YANK
|n 10754245
|
994 |
|
|
|a 92
|b IZTAP
|